Faculty, Staff and Student Publications

Language

English

Publication Date

4-1-2026

Journal

Magnetic Resonance in Medicine

DOI

10.1002/mrm.70188

PMID

41266946

PMCID

PMC12850612

PubMedCentral® Posted Date

11-20-2025

PubMedCentral® Full Text Version

Post-print

Abstract

Purpose: To investigate contrast-enhanced T1-weighted MRI and diffusion-weighted magnetic resonance imaging (DWI) for early prediction of tumor response to combined irreversible electroporation (IRE) and anti-PD-1 immunotherapy.

Methods: Murine pancreatic ductal adenocarcinoma (PDAC) cells KRAS* were inoculated into the pancreas of C57BL/6 mice. IRE was performed when tumors became palpable. After IRE, mice received six intraperitoneal injections of anti-PD-1 over 2 weeks. T2-weighted MRI, T1-weighted MRI with macromolecular contrast agent poly(L-glutamic acid)-conjugated gadolinium (PG-Gd), and DWI were performed before and after IRE. Survival was analyzed using Kaplan-Meier curves. Mice surviving at least 100 days without recurrence after IRE were considered complete responders. Relationships between MRI findings and treatment response were assessed with one-way ANOVA, Student's t-test, and receiver operating characteristic (ROC) analysis.

Results: Tumor volume on T2-weighted MRI at early treatment time-points did not correlate with survival. T1-weighted MRI with PG-Gd clearly showed increased PG-Gd uptake in tumors on days 4 and 11-14 after IRE and anti-PD-1 immunotherapy. Higher PG-Gd uptake correlated with longer survival (R2 = 0.634; p < 0.0001). Area-under-the-ROC curve had high predictive value for treatment outcome (0.805; p = 0.033). Immunofluorescence staining confirmed high accumulation of macrophages in tumors after treatment. On DWI, all KRAS* tumors exhibited significantly increased apparent diffusion coefficient (ADC) values 7, 11, and 14 days after combination therapy. Moreover, pretreatment tumor ADC values were significantly higher in complete responders than in partial responders (p = 0.0025).

Conclusion: PG-Gd contrast-enhanced T1-weighted MRI and DWI are potential predictors of response to combined IRE and anti-PD-1 immunotherapy in PDAC.

Keywords

Animals, Carcinoma, Pancreatic Ductal, Mice, Pancreatic Neoplasms, Electroporation, Mice, Inbred C57BL, Immunotherapy, Multiparametric Magnetic Resonance Imaging, Cell Line, Tumor, Diffusion Magnetic Resonance Imaging, Treatment Outcome, Contrast Media, Female, Programmed Cell Death 1 Receptor, Immune Checkpoint Inhibitors, anti‐PD‐1, contrast‐enhanced T1‐weighted MRI, diffusion‐weighted MRI, irreversible electroporation, T2‐weighted MRI

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.